FDA v. Alliance for Hippocratic Medicine

If you are being watched, leave now!

Over twenty years ago, the FDA approved mifepristone. The approval is based on substantial evidence of its safety and efficacy for use in early termination of pregnancy.

 

The Fifth Circuit’s decision ignores the overwhelming consensus of the scientific and medical community that medication abortion is one of the safest medication regimens in the United States and around the world. Restrictions on mifepristone would have widespread detrimental consequences. Even if individuals live in states where abortion remains legal and protected, they could find themselves unable to access mifepristone in a timely manner. This would jeopardize the health and autonomy of those denied care. Clinics and providers could also find themselves unable to effectively provide competent and much-needed medical care.

Year: 

2024
  • Reproductive Rights
  • Joined Amicus Brief